SNT 2.27% 4.3¢ syntara limited

Ann: Investor presentation, page-26

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 12,240 Posts.
    lightbulb Created with Sketch. 6238
    SNT 6302 is my focus ,, even though they have 4 x Phase II in action all funded till mid 2025,,, yes I could see them raising in December off the back of the SNT 6302 as that will be a High Valued Catalyst...

    Afternoon @ma420

    This is a slightly longer play for me than usual , I'm not after a fixed margin trade here of 20% , have been adding to my holding over the past month.

    The Scaring and Burns treatment is a highly visual and easily understood treatment, recruitment is now completed, the Phase I results Principal Investigator Comment Below
    “SNT-6302 leads directly to an unprecedented change to the scar composition that we have not seen with any other form of treatment.”

    Professor Fiona Wood
    Burns Service of Western Australia
    Director of the Burn Injury Research Unit
    University of Western Australia

    Example of Strong Visuals to Follow
    Repair-burn-shoulder.png?v=1681412250

    Last edited by NZ Trader: 05/07/24
 
watchlist Created with Sketch. Add SNT (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.